title: Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis.
abstract: BACKGROUND
  Unlike Goodpasture's syndrome with diffuse alveolar hemorrhage (DAH), there are few studies examining therapy for patients with DAH associated with antineutrophil cytoplasmic antibody (ANCA)-associated small-vessel vasculitis (SVV).
  
  
  METHODS
  We performed a retrospective review of all such patients presenting to our institution between 1995 and 2001. All patients were treated with apheresis and induction immunosuppressive therapy; namely, intravenous methylprednisolone and/or intravenous cyclophosphamide.
  
  
  RESULTS
  DAH resolved with apheresis in 20 of 20 patients (100%) with 6.4 (average) treatments. There were no complications of therapy. Half the patients (7 of 14) who also presented with azotemia were discharged with improved renal function.
  
  
  CONCLUSIONS
  Patients with ANCA-related SVV and DAH benefit from prompt initiation of apheresis coupled with aggressive immunosuppressive therapy. Such therapy can be lifesaving with respect to the pulmonary component of this syndrome.
authors.affiliation: Division of Nephrology and Hypertension, University of North Carolina, Chapel Hill 27599-7155, USA. philip_klemmer@med.unc.edu
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Klemmer
authors.forename: W
authors.initials: W
authors.lastname: Chalermskulrat
authors.forename: Michael S
authors.initials: MS
authors.lastname: Reif
authors.forename: Susan L
authors.initials: SL
authors.lastname: Hogan
authors.forename: David C
authors.initials: DC
authors.lastname: Henke
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Falk
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000276:immunology*; D001327:Autoimmune Diseases / Q000209:etiology / Q000628:therapy*; D015267:Churg-Strauss Syndrome / Q000150:complications / Q000188:drug therapy; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D014890:Granulomatosis with Polyangiitis / Q000150:complications / Q000188:drug therapy; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008171:Lung Diseases / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D010956:Plasmapheresis; D011650:Pulmonary Alveoli; D012189:Retrospective Studies; D016896:Treatment Outcome; D014657:Vasculitis / Q000150:complications* / Q000188:drug therapy
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D008775:Methylprednisolone